Meeting
2014 ASCO Annual Meeting
Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).
Authors
Yoichi Naito
National Cancer Center Hospital East, Chiba, Japan
Yoichi Naito , Akira Kawai , Nobuhito Araki , Toshifumi Ozaki , Hideshi Sugiura , Yasuo Yazawa , Hideo Morioka , Akihiko Matsumine , Masahide Hiraiwa , Shun Asami , Kazuo Isu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01458249
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10567)
DOI
10.1200/jco.2014.32.15_suppl.10567
Abstract #
10567
Poster Bd #
274
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2024 ASCO Annual Meeting
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.
First Author: Jie Liu
Poster
2022 ASCO Annual Meeting
Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).
First Author: Roberta Sanfilippo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.
First Author: Ting Han